United Therapeutics | UTHR - Cash And Equivalent


United Therapeutics reported $1.34B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Amarin USD 122.8M 25.08M Sep/2025
Ardelyx USD 42.72M 47.32M Sep/2025
Baxter International USD 1.73B 40M Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Insmed USD 334.76M 949.56M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025